Corrigendum to "Fhit loss in lung preneoplasia: Relation to DNA damage response checkpoint activation" [Cancer Lett. 291 (2) (2010) 230-236] DOI: 10.1016/j.canlet.2009.10.017;Fhit loss in lung preneoplasia: Relation to DNA damage response checkpoint activation

Cancer Letters

Volumn 291, Issue 2, 2010, Pages 230-236

  Cirombella, Roberto ^a   Montrone, Giuseppe ^b   Stoppacciaro, Antonella ^a   Giglio, Simona ^a   Volinia, Stefano ^c   Graziano, Paolo ^b   Huebner, Kay ^c   Vecchione, Andrea ^a,c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^c and Sociology   (United States)

Author keywords

Chromosome fragile sites; DNA damage response checkpoint; Fhit; Preneoplastic lesions of lung; Squamous dysplasia

Indexed keywords

CHECKPOINT KINASE 1; FRAGILE HISTIDINE TRIAD PROTEIN; HISTONE H2AX;

ARTICLE; CONTROLLED STUDY; DNA DAMAGE; HETEROZYGOSITY LOSS; HYPERPLASIA; LUNG CANCER; LUNG DYSPLASIA; LUNG NON SMALL CELL CANCER; PRECANCER; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SCORING SYSTEM;

EID: 77950021721     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.09.001     Document Type: Erratum

References (33)

1. Tsantoulis P.K., Kotsinas A., Sfikakis P.P., Evangelou K., Sideridou M., Levy B., Mo L., Kittas C., Wu X.R., Papavassiliou A.G., and Gorgoulis V.G. Oncogene-induced replication stress preferentially targets common fragile sites in preneoplastic lesions. A genome-wide study. Oncogene 27 (2008) 3256-3264
2. Thavathiru E., Ludes-Meyers J.H., MacLeod M.C., and Aldaz C.M. Expression of common chromosomal fragile site genes WWOX/FRA16D and FHIT/FRA3B is downregulated by exposure to environmental carcinogens UV and BPDE but not by IR. Mol. Carcinogen. 44 (2005) 174-182
3. Guler G., Uner A., Guler N., Han S.Y., Iliopoulos D., Hauck W.W., McCue P., and Huebner K. The fragile genes, FHIT and WWOX, are inactivated coordinately in invasive breast carcinoma. Cancer 100 (2004) 1605-1614
4. Sozzi G., Pastorino U., Moiraghi L., Tagliabue E., Pezzella F., Ghirelli C., Tornielli S., Sard L., Huebner K., Pierotti M.A., Croce C.M., and Pilotti S. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res. 58 (1998) 5032-5037
5. Tseng J.E., Kemp B.L., Khuri F.R., Kurie J.M., Lee J.S., Zhou X., Liu D., Hong W.K., and Mao L. Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers. Cancer Res. 59 (1999) 4798-4803
6. Wistuba I.I., Behrens C., Virmani A.K., Mele G., Milchgrub S., Girard L., Fondon III J.W., Garner H.R., McKay B., Latif F., Lerman M.I., Lam S., Gazdar A.F., and Minna J.D. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res. 60 (2000) 1949-1960
7. Kitamura A., Yashima K., Okamoto E., Andachi H., Hosoda A., Kishimoto Y., Shiota G., Ito H., Kaibara N., and Kawasaki H. Reduced Fhit expression occurs in the early stage of esophageal tumorigenesis: no correlation with p53 expression and apoptosis. Oncology 61 (2001) 205-211
8. Zhao P., Liu W., and Lu Y.L. Clinicopathological significance of FHIT protein expression in gastric adenocarcinoma patients. World J. Gastroenterol. 11 (2005) 5735-5738
9. Butler D., Collins C., Mabruk M., Leader M.B., and Kay E.W. Loss of Fhit expression as a potential marker of malignant progression in preinvasive squamous cervical cancer. Gynecol. Oncol. 86 (2002) 144-149
10. Connolly D.C., Greenspan D.L., Wu R., Ren X., Dunn R.L., Shah K.V., Jones R.W., Bosch F.X., Muñoz N., and Cho K.R. Loss of fhit expression in invasive cervical carcinomas and intraepithelial lesions associated with invasive disease. Clin. Cancer Res. 6 (2000) 3505-3510
11. Gorgoulis V.G., Vassiliou L.V., Karakaidos P., Zacharatos P., Kotsinas A., Liloglou T., Venere M., Ditullio Jr. R.A., Kastrinakis N.G., Levy B., Kletsas D., Yoneta A., Herlyn M., Kittas C., and Halazonetis T.D. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434 (2005) 907-913
12. Bartkova J., Horejsi Z., Koed K., Krämer A., Tort F., Zieger K., Guldberg P., Sehested M., Nesland J.M., Lukas C., Ørntoft T., Lukas J., and Bartek J. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434 (2005) 864-870
13. Bartek J., Bartkova J., and Lukas J. DNA damage signaling guards against activated oncogenes and tumour progression. Oncogene 26 (2007) 7773-7779
14. Ishii H., Mimori K., Inoue H., Inageta T., Ishikawa K., Semba S., Druck T., Trapasso F., Tani K., Vecchione A., Croce C.M., Mori M., and Huebner K. Fhit modulates the DNA damage checkpoint response. Cancer Res. 66 (2006) 11287-11292
15. Pichiorri F., Ishii H., Okumura H., Trapasso F., Wang Y., and Huebner K. Molecular parameters of genome instability: roles of fragile genes at common fragile sites. J. Cell. Biochem. 104 (2008) 1525-1533
16. Yutori H., Semba S., Kumori T., and Yokozaki H. Restoration of fragile histidine triad expression restores Chk2 activity in response to ionizing radiation in oral squamous cell carcinoma cells. Cancer Sci. 99 (2008) 524-530
17. Hammond E.M., Dorie M.J., and Giaccia A.J. ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation. J. Biol. Chem. 278 (2003) 12207-12213
18. Cliby W.A., Roberts C.J., Cimprich K.A., Stringer C.M., Lamb J.R., Schreiber S.L., and Friend S.H. Overexpression of a kinaseinactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints. EMBO J. 17 (1998) 159-169
19. Ahn J.Y., Schwarz J.K., Piwnica-Worms H., and Canman C.E. Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res. 60 (2000) 5934-5936
20. Matsuoka S., Huang M., and Elledge S.J. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282 (1998) 1893-1897
21. Helt C.E., Cliby W.A., Keng P.C., Bambara R.A., and O'Reilly M.A. Ataxia telangiectasia mutated (ATM) and ATM and Rad3-related protein exhibit selective target specificities in response to different forms of DNA damage. J. Biol. Chem. 280 (2005) 1186-1192
22. Durkin S.G., Arlt M.F., Howlett N.G., and Glover T.W. Depletion of CHK1, but not CHK2, induces chromosomal instability and breaks at common fragile sites. Oncogene 25 (2006) 4381-4388
23. Arlt M.F., Durkin S.G., Ragland R.L., and Glover T.W. Common fragile sites as targets for chromosome rearrangements. DNA Repair (Amst) 5 (2006) 1126-1135 (Review)
24. Rom W.N., Hay J.G., Lee T.C., Jiang Y., and Tchou-Wong K.M. Molecular and genetic aspects of lung cancer. Am. J. Respir. Crit. Care Med. 161 (2000) 1355-1367
25. Alberts W.M. Introduction: diagnosis and management of lung cancer: ACCP evidence-based clinical practice guidelines. Chest 132 (2007) 20S-22S
26. Patz Jr. E.F., Goodman P.C., and Bepler G. Screening for lung cancer. New Engl. J. Med. 343 (2000) 1627-1633
27. Wistuba I.I., and Gazdar A.F. Lung cancer preneoplasia. Annu. Rev. Pathol. 1 (2006) 331-348
28. Durkin S.G., Ragland R.L., Arlt M.F., Mulle J.G., Warren S.T., and Glover T.W. Replication stress induces tumor-like microdeletions in FHIT/FRA3B. Proc. Natl. Acad. Sci. USA 105 (2008) 246-251
29. Indinnimeo M., Giarnieri E., Stazi A., Cicchini C., Brozzetti S., Valli C., Carreca I., and Vecchione A. Early stage human colorectal cancer: prognostic value of nm23-H1 protein overexpression. Cancer Lett. 111 (1997) 1-5
30. Holm S. A simple sequentially rejective multiple test procedure. Scand. J. Stat. 6 (1979) 65-70
31. Stucki M., and Jackson S.P. GammaH2AX and MDC1: anchoring the DNA-damage-response machinery to broken chromosomes. DNA Repair (Amst) 5 (2006) 534-543
32. Verri C., Roz L., Conte D., Liloglou T., Livio A., Vesin A., Fabbri A., Andriani F., Brambilla C., Tavecchio L., Calarco G., Calabrò E., Mancini A., Tosi D., Bossi P., Field J.K., Brambilla E., Sozzi G., and Consortium E.U.E.L.C. Fragile histidine triad gene inactivation in lung cancer: the European Early Lung Cancer project. Am. J. Respir. Crit. Care Med. 179 (2009) 396-401
33. Lord C.J., and Ashworth A. Targeted therapy for cancer using PARP inhibitors. Curr. Opin. Pharmacol. 8 (2008) 363-369 (Review)